Our results reflect those of Humbert et al8 who saw a large variability in blood flow response in HER2 negative tumours after one cycle of EC chemotherapy (HER2 positive patients in that study experienced a large decrease in blood flow but they were selectively treated with docetaxel and trastuzumab). This evidence concerns the gene ERBB2 and neoplasm.